enGene(NASDAQ) ENGNW

Market CapN/A

Since IPO (2022)-16%

5 YearN/A

1 Year-59%

1 Month+29%

$0.32

+0.57%

+0.00Today

enGene last closing stock price
Metric	Price	Date
Last close	USD 0.36	2026-07-24

enGene stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+12.04%	USD 0.32	2026-07-17
1 month	+28.66%	USD 0.28	2026-06-18
3 month	-85%	USD 2.40	2026-04-24
Year to date	-87.84%	USD 2.96	2025-12-30
1 year	-59.04%	USD 0.88	2025-07-24
3 year	-26.53%	USD 0.49	2023-07-19
Since inception	-16.28%	USD 0.43	2022-02-01

enGene Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$0.00

Net Income (TTM)

-$66.40M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.91 (Low)

Dividend

$0.00

Beta (Volatility)

0.91 (Low)

Price

$0.32

Volume

Open

$0.32

Price

$0.32

Volume

Open

$0.32

Previous Close

$0.32

Daily Range

$0.32 - $0.32

52-Week Range

$0.11 - $4.20

Estimated Earnings Date

Sep 16, 2026

Dividend

$0.00

Beta (Volatility)

0.91 (Low)

Price

$0.32

Volume

Open

$0.32

Previous Close

$0.32

Daily Range

$0.32 - $0.32

52-Week Range

$0.11 - $4.20

Estimated Earnings Date

Sep 16, 2026

ENGNW News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About enGene

enGene Holdings Inc. is a clinical-stage biotechnology company focused on advancing genetic medicines. The company specializes in innovative therapies for targeted delivery to mucosal tissues and other organs, with a primary focus on treating non-muscle invasive bladder cancer.

Products and Services

EG-70 (detalimogene voraplasmid) for bladder cancer treatment
Targeted delivery systems for genetic therapies
Research and development in immunotherapy

Growth Outlook

Strong pipeline with EG-70 targeting unmet medical needs
Potential for expansion into other therapeutic areas
Increasing interest in genetic medicine and immunotherapy markets

Financial Highlights

Recent quarterly net income of -$30.2 million
Cash and short-term investments totaling $258.5 million
Current ratio of 12.57 indicates strong liquidity position

AI Generated • Jul 19, 2026

Industry

Biotechnology

Sector

Health Care

Headquarters

Montreal, QC H4S 1Z9, CA

ENGNW Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-29.34%

Return on Capital

-61.74%

Return on Assets

-21.59%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

Volume

Avg. Volume

13.21K

Financials (TTM)

Gross Profit

-$369.00K

Operating Income

-$68.65M

EBITDA

-$125.94M

Operating Cash Flow

-$110.00M

Capital Expenditure

-$1.39M

Free Cash Flow

-$111.39M

Cash & ST Invst.

$258.47M

Total Debt

$33.35M

enGene Performance Analysis

enGene sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-07-31	N/A
Q4	2025-10-31	N/A
Q1	2026-01-31	N/A
Q2	2026-04-30	N/A

enGene sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-07-31	-211.8%
Q4	2025-10-31	-29.8%
Q1	2026-01-31	40.5%
Q2	2026-04-30	197.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$180.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

N/A

Market Cap/Employee

N/A

Employees

N/A

Net Income

$30.23M

+217.1%

EBITDA

-$31.79M

-28.5%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$258.47M

+18.9%

Total Debt

$33.35M

+31.5%

Accounts Receivable

$2.92M

+448.2%

Inventory

$0.00

N/A

Long Term Debt

$30.87M

+44.5%

Short Term Debt

$2.48M

-38.0%

Return on Assets

-21.59%

N/A

Return on Invested Capital

-24.00%

N/A

Free Cash Flow

-$30.60M

-33.1%

Operating Cash Flow

-$30.50M

-32.9%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

HYFTMindWalk Holdings Corp.

HYFTMindWalk Holdings Corp.$1.44+5.88%

ALXOALX Oncology Holdings Inc.

ALXOALX Oncology Holdings Inc.$2.02-0.49%

BYSIBeyondSpring Inc.

BYSIBeyondSpring Inc.$1.17+4.46%

CAMPCAMP4 Therapeutics Corporation

CAMPCAMP4 Therapeutics Corporation$3.42+8.23%

RPTXRepare Therapeutics Inc.

RPTXRepare Therapeutics Inc.$2.65+0.00%

BMEABiomea Fusion, Inc.

BMEABiomea Fusion, Inc.$1.26+0.80%

UNCYUnicycive Therapeutics, Inc.

UNCYUnicycive Therapeutics, Inc.$5.13-5.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

INTCIntel

INTCIntel$91.67-0.01%

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$5.25+0.10%

NOKNokia

NOKNokia$9.28+0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$14.95+0.03%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.24-0.02%

TAT&T

TAT&T$24.42+0.01%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$63.40-0.01%

Questions About ENGNW

What is the current price of enGene?

enGene is trading at $0.32 per share.

What is the 52-week range for enGene?

Over the past 52 weeks, enGene has traded between $0.11 and $4.20.

How much debt does enGene have?

enGene total debt is unavailable.

How much cash does enGene have on hand?

enGene does not have cash on hand data available.

What is enGene’s dividend yield?

enGene does not currently have a dividend yield.

enGene(NASDAQ) ENGNW

enGene Financials at a Glance

ENGNW News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About enGene

ENGNW Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

enGene Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ENGNW

What is the current price of enGene?

What is the 52-week range for enGene?

How much debt does enGene have?

How much cash does enGene have on hand?

What is enGene’s dividend yield?

Premium Investing Services